ALEC — Alector, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1653087 ·
Last close
$2.19
Market Cap
$243.15M
52W High
$2.74
52W Low
$1.89
ADV30
552,977
Next earnings
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,046,000 -24,919,000 -22,930,000 239,916,000 76,962,000 229,534,000
Dec 2025 6,237,000 -39,566,000 -37,267,000 293,237,000 65,802,000 262,588,000
Sep 2025 3,260,000 -37,608,000 -34,667,000 335,285,000 76,503,000 277,573,000
Jun 2025 7,874,000 -34,138,000 -30,524,000 356,422,000 44,771,000 285,247,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-184,031,000
Investing CF
$196,597,000
Financing CF
$20,215,000
CapEx
$-214,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.39
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-972,056,000
Inventory
Receivables
ST Investments
$190,222,000
EBIT TTM
$-156,007,000
Pretax Income TTM
$-142,761,000
Interest Exp TTM
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$18,417,000
EBITDA
$-127,494,000
Free Cash Flow
$-119,106,128
Enterprise Value
$73,398,664
Total Cash
$206,515,008
Total Debt
$34,548,000
Shares Out
111,025,187
Trailing EPS
$-1.18
Book Value
$0.09
ROE
-238.9%
ROA
-25.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 21,045,000 -156,007,000 -142,929,000 293,237,000 262,588,000 -184,031,000
Dec 2024 100,558,000 -144,997,000 -119,049,000 468,303,000 341,503,000 -229,905,000
Dec 2023 97,062,000 -151,740,000 -130,391,000 621,827,000 487,669,000 -184,162,000
Dec 2022 133,617,000 -137,834,000 -133,310,000 787,648,000 573,206,000 -20,329,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.70

Peers — same industry

TickerNameMarket CapLastDaily %
LENZ LENZ Therapeutics, Inc. $243.00M $7.75
HUMA Humacyte, Inc. $246.44M $1.11
FATE FATE THERAPEUTICS INC $250.60M $2.15
CGEN COMPUGEN LTD $250.65M $2.65
AVXL ANAVEX LIFE SCIENCES CORP. $251.14M $2.71

News headlines (Yahoo Finance, 1h cache)

How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
2026-05-19 04:34 · Yahoo
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 20:05 · Yahoo
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
2026-05-07 14:00 · Yahoo
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-05 12:25 · Yahoo
GSK Juggles Alzheimer’s Setback And Leadership Shift With Product Progress
2026-05-03 01:19 · Yahoo
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
2026-04-30 12:08 · Yahoo
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
2026-04-29 20:05 · Yahoo
Discovering Middle East's Undiscovered Gems This April 2026
2026-04-28 03:33 · Yahoo
Undiscovered Gems in the Middle East for March 2026
2026-03-26 08:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.